NXTC
NextCure IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$39.73M
P/E Ratio
—
EPS
$-19.65
Beta
1.58
52W High
$15.74
52W Low
$3.25
50-Day MA
$11.85
200-Day MA
$9.10
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-54.20M |
| EBITDA | $-55.43M |
| Operating Margin | 0.00% |
| Return on Equity | -111.20% |
| Return on Assets | -55.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.97 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 9.52 |
| EV/Revenue | 117.33 |
| EV/EBITDA | 0.51 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $3.56M |
| Float | $2.23M |
| % Insiders | 15.18% |
| % Institutions | 49.04% |
Analyst Ratings
Consensus ($17.67 target)
1
Strong Buy2
BuyData last updated: 4/9/2026